Immunis, Inc.
PrivateLast Round
Seed Round
Jun 15, 2026
Est. Valuation
$30M
Total Funding Raised
$35.25M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Immunis, Inc. is a biotechnology company that develops multi-active biologics derived from stem cell secretomes to address age-related diseases and immune dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunis, Inc. Comparables
Compare Immunis, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 84% | |
| Remedy Cell Ltd. | 76% | |
| Direct Biologics | 72% |
Immunis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 15, 2026 | ||||
| Grant | May 12, 2025 | ||||
| Series A Extension | Jan 11, 2025 | ||||
| Series A | Aug 3, 2022 |
Immunis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A Extension, Series A |
| BOLD Capital Partners | Series A Extension |
| X PRIZE Foundation | Grant |
| Continuum Health Ventures | Series A Extension, Series A |
| LifeSpan Vision Ventures | Series A Extension |
| JLS Fund | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors increased 34% MoM.
- Jul 15, 2026
Grew 22% QoQ, from 18 to 22 employees.
Recent news
Latest coverage and updates
- receives_awardOct 21, 2026
Immunis, Inc. is selected to receive the National Academy of Medicine's Grand Prize in its Healthy Longevity Global Competition on Oct 21st '26 for IMM01-STEM and its potential to restore muscle function, metabolic health, and quality of life as people age.
- is_developingOct 21, 2026
As of Oct 21st '26, Immunis, Inc. is developing IMM01-STEM, a multi-pathway biologic in a randomized Phase 2 clinical trial, to help preserve strength, mobility, and metabolic health as people age.
- recognized_asOct 13, 2026
In California on Oct 13th '26, Immunis, Inc. announces that the U.S. National Academy of Medicine selects it as a semifinalist in the Grand Prize Phase of its Healthy Longevity Global Competition, advancing from a field of 720 Catalyst Award recipients worldwide.
- receives_awardOct 13, 2026
Immunis, Inc. previously received a Healthy Longevity Catalyst Award through the National Academy of Medicine’s Healthy Longevity Global Competition for exploring multi-active secretomes to reverse muscle atrophy and metabolic decline.
- recognized_asOct 13, 2026
On Oct 14th '26 in California, Immunis, Inc. is selected by the U.S. National Academy of Medicine as a semifinalist in the Grand Prize Phase of its Healthy Longevity Global Competition, advancing from a field of 720 Catalyst Award recipients worldwide.
Immunis, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immunis, Inc.'s valuation, stock price, and market status.
Is Immunis, Inc. a public or private company?
Immunis, Inc. is a private company.
What is the current stock price of Immunis, Inc.?
Immunis, Inc. is a private company, so its shares have no public market price. Caplight tracks Immunis, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunis, Inc. worth (valuation)?
Immunis, Inc.'s valuation is estimated at $30.0M based on funding round data.
Can I buy Immunis, Inc. stock?
Immunis, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunis, Inc.'s last funding round?
Immunis, Inc.'s most recent funding round was Seed Round on June 15, 2026.
Who are the main investors in Immunis, Inc.?
Key investors in Immunis, Inc. include Remiges Ventures.
Will Immunis, Inc. IPO soon?
No public IPO plans have been announced for Immunis, Inc..
How can I track Immunis, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Immunis, Inc.'s shares on secondary markets.